MindWalk (HYFT)
Combines biological context, AI software, and wet-lab research for drug discovery.
$1.36
At close+0.06 (+4.62%)
In millions of USD, except per-share figures · converted from CAD at the latest rate
| In millions | Q1 FY24Aug 2023 | Q2 FY24Oct 2023 | Q3 FY24Jan 2024 | Q4 FY24Apr 2024 | Q1 FY25Jul 2024 | Q2 FY25Oct 2024 | Q3 FY25Jan 2025 | Q4 FY25Apr 2025 | Q1 FY26Jul 2025 | Q2 FY26Oct 2025 | Q3 FY26Jan 2026 | Q4 FY26Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 4 | 5 | 5 | 2 | 2 | 4 | 5 | 2 | 3 | 3 | 3 |
| Cost of revenue | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Gross profit | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 2 |
| 2 | 4 | 5 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 5 | |
| Research & development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 4 | |
| Selling & marketing | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| General & administrative | 3 | 2 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 2 | 0 | 0 |
| Other expenses | −2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 0 | −2 | −2 | −3 | −3 | −3 | −2 | −1 | −3 | −2 | −3 | −3 |
| −3 | 0 | 0 | −11 | 0 | 0 | −15 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 3 | 0 | 0 | 11 | 0 | 0 | 15 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −3 | −2 | −3 | −14 | −4 | −3 | −18 | −1 | −3 | −2 | −3 | — |
| Income tax expense | 0 | 0 | −1 | −1 | 0 | −1 | −2 | 0 | 0 | 0 | 0 | — |
| Net income from continuing operations | −2 | −2 | −2 | −13 | −3 | −3 | −16 | −2 | −3 | −2 | −3 | — |
| Discontinued operations | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Net income | −2 | −2 | −2 | −13 | −3 | −2 | −16 | −2 | −2 | −2 | −3 | — |
| EPS, basic | −$0.10 | −$0.07 | −$0.07 | −$0.48 | −$0.11 | −$0.07 | −$0.49 | −$0.05 | −$0.05 | −$0.05 | −$0.06 | −$0.06 |
| EPS, diluted | −$0.10 | −$0.07 | −$0.07 | −$0.48 | −$0.11 | −$0.07 | −$0.49 | −$0.05 | −$0.05 | −$0.05 | −$0.06 | −$0.06 |
| Weighted average shares, basic | 25 | 25 | 26 | 27 | 27 | 28 | 33 | 33 | 40 | 46 | 47 | 47 |
| Weighted average shares, diluted | 25 | 25 | 26 | 27 | 27 | 28 | 33 | 33 | 40 | 46 | 47 | 47 |
| EBITDA | −2 | −1 | −2 | −12 | −3 | −2 | −17 | −1 | −2 | −2 | −3 | −3 |
| Depreciation & amortization | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| EBIT | −3 | −2 | −2 | −14 | −4 | −3 | −18 | −1 | −3 | −2 | −3 | −3 |